

## CONTENTS

---

1. Introduction.	1
2. State of Art.	3
2.1. Overview.	3
2.2. K <sub>2P</sub> channels topology and structure.	5
2.3. TASK subfamily physiology.	9
2.4. TASK channels pharmacology.	10
3. Hypothesis.	13
4. Objectives.	14
5. Chapter I: Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?	15
5.1. Introduction.	15
5.2. Materials and Methods.	17
5.3. Results.	18
5.4. Discussion.	27
5.5. Future work.	31
5.6. Scientific production.	32
6. Chapter II: Side fenestration provide and ‘anchor’ for stable binding of A1899 to the pore of TASK-1 potassium channels.	33
6.1. Introduction.	33
6.2. Materials and Methods.	35
6.3. Results.	40
6.4. Discussion.	51
6.5. Future work.	54
6.6. Scientific production.	55
7. Chapter III: Structure-based discovery of potential two-pore domain potassium channels TASK-3 modulators.	56
7.1. Introduction.	56
7.2. Materials and Methods.	59
7.3. Results.	65
7.4. Discussion.	77
7.5. Future work.	81
7.6. Scientific production.	82
8. Chapter IV: Additional Studies.	83
9. Concluding Remarks.	91
10. References.	93
11. Appendix A: Abbreviations and acronyms.	108
12. Appendix B: Supplemental information of Chapter II.	111
13. Appendix C: Supplemental information of Chapter III.	123

## LIST OF FIGURES

---

Figure 1. $K_{2P}$ subfamilies in <i>Homo sapiens</i> .	4
Figure 2. $K_{2P}$ channels topology.	5
Figure 3. Architecture of $K_{2P}$ channels.	6
Figure 4. Chemical structures of Kv1.5 blockers and their affinity for Kv1.5 and TASK-1.	19
Figure 5. Sequence alignment and cartoon illustrating the drug binding site of Kv1.5 and TASK-1.	21
Figure 6. The drug binding sites of Kv1.5 and TASK-1 illustrated in pore homology models.	23
Figure 7. Diameter of the cytosolic opening to the central cavity and analysis of the frequency-dependent inhibition of Kv1.5 and TASK-1.	25
Figure 8. Common pharmacophore for the TASK-1 blockers AVE0118, S20951 (A1899), S9947, AVE1231 (A293), and MSD-D.	26
Figure 9. Characterization of the side fenestration in TASK-1 models.	41
Figure 10. Ordering of A1899 docking solutions in TASK-1 by cluster analyses.	44
Figure 11. Ordering A1899 poses of significant clusters by their free binding energy.	45
Figure 12. Contacts of A1899 with residues of the TASK-1 binding site and the nature of the chemical interaction.	47
Figure 13. Redefined binding mode of A1899 in TASK-1 includes residues that contribute to the side fenestrations.	48
Figure 14. A1899 stabilizes the pen fenestration of TASK-1.	49
Figure 15. A1899 does not pass the side fenestration to reach the binding site.	50
Figure 16. RMSD for backbones of TASK-3 models during MD simulations.	66
Figure 17. Fenestration states in T3trCO.	67
Figure 18. Common e-Pharmacophore for the TASK-3 reported blockers $_K$ -THPP, A1899, Doxapram, Loratadine and L-703,606.	69
Figure 19. Biological activity validation.	71
Figure 20. DR6 binding mode.	73
Figure 21. DR17 binding mode.	75
Scheme 1. Systematic representation of the workflow to identify TASK-3 modulators.	58

## LIST OF TABLES

---

Table 1. Nomenclature of the TASK-1 homology models.	36
Table 2. TASK-1 residues in the fenestration (F) and the Pore during the MDs – HOLE results.	42
Table 3. Significant clusters in TASK-1 models.	43
Table 4. Nomenclature of the TASK-3 homology models.	59
Table 5. Reported TASK-3 modulators.	61
Table 6. e-Pharmacophore hypotheses.	69
Table 7. Ligands hits interacting with TASK-3 homology models.	70
Table 8. Location of the interacting residues of DR6 and DR17 in TASK-3 models.	72
Table 9. Physicochemical descriptor calculated by QikProp simulation.	76
Table 10. Pharmacokinetics properties predicted by QikProp simulation.	77